Precision Biosciences Inc (DTIL)

$7.16

-0.1

(-1.38%)▲

Market is closed - opens 8 PM, 20 Nov 2024

Performance

  • $7.07
    $7.33
    $7.16
    downward going graph

    1.26%

    Downside

    Day's Volatility :3.55%

    Upside

    2.32%

    downward going graph
  • $7.07
    $19.43
    $7.16
    downward going graph

    1.26%

    Downside

    52 Weeks Volatility :63.61%

    Upside

    63.15%

    downward going graph

Returns

PeriodPrecision Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-19.1%
-8.6%
0.0%
6 Months
-44.24%
-3.3%
0.0%
1 Year
-46.73%
9.4%
0.0%
3 Years
-97.4%
6.2%
-24.5%

Highlights

Market Capitalization
55.7M
Book Value
$8.67
Earnings Per Share (EPS)
0.4
PE Ratio
18.15
Wall Street Target Price
35.75
Profit Margin
11.48%
Operating Margin TTM
-3693.58%
Return On Assets TTM
-6.38%
Return On Equity TTM
24.44%
Revenue TTM
75.1M
Revenue Per Share TTM
12.87
Quarterly Revenue Growth YOY
-95.6%
Gross Profit TTM
25.1M
EBITDA
-12.0M
Diluted Eps TTM
0.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.03
EPS Estimate Next Year
-8.62
EPS Estimate Current Quarter
-1.92
EPS Estimate Next Quarter
-1.67

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Precision Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 399.3%

Current $7.16
Target $35.75

Company Financials

FY18Y/Y Change
Revenue
10.9M
↑ 67.84%
Net Income
-46.0M
↑ 118.16%
Net Profit Margin
-423.02%
↓ 97.57%
FY19Y/Y Change
Revenue
22.2M
↑ 104.34%
Net Income
-83.3M
↑ 80.94%
Net Profit Margin
-374.59%
↑ 48.43%
FY20Y/Y Change
Revenue
24.3M
↑ 9.2%
Net Income
-109.0M
↑ 30.86%
Net Profit Margin
-448.86%
↓ 74.27%
FY21Y/Y Change
Revenue
115.5M
↑ 375.72%
Net Income
-30.9M
↓ 71.64%
Net Profit Margin
-26.76%
↑ 422.1%
FY22Y/Y Change
Revenue
25.1M
↓ 78.28%
Net Income
-122.9M
↑ 297.53%
Net Profit Margin
-489.71%
↓ 462.95%
FY23Y/Y Change
Revenue
48.7M
↑ 94.15%
Net Income
-61.3M
↓ 50.11%
Net Profit Margin
-125.84%
↑ 363.87%
Q2 FY23Q/Q Change
Revenue
19.8M
↑ 125.39%
Net Income
-11.9M
↓ 49.52%
Net Profit Margin
-60.09%
↑ 208.22%
Q3 FY23Q/Q Change
Revenue
13.1M
↓ 33.7%
Net Income
-8.1M
↓ 32.06%
Net Profit Margin
-61.58%
↓ 1.49%
Q4 FY23Q/Q Change
Revenue
7.0M
↓ 46.36%
Net Income
-16.3M
↑ 101.62%
Net Profit Margin
-231.44%
↓ 169.86%
Q1 FY24Q/Q Change
Revenue
17.6M
↑ 149.84%
Net Income
8.6M
↓ 152.72%
Net Profit Margin
48.84%
↑ 280.28%
Q2 FY24Q/Q Change
Revenue
49.9M
↑ 183.77%
Net Income
32.7M
↑ 281.33%
Net Profit Margin
65.63%
↑ 16.79%
Q3 FY24Q/Q Change
Revenue
576.0K
↓ 98.85%
Net Income
-16.4M
↓ 150.15%
Net Profit Margin
-2.9K%
↓ 2917.19%
FY18Y/Y Change
Total Assets
138.6M
↑ 90.69%
Total Liabilities
98.6M
↓ 0.41%
FY19Y/Y Change
Total Assets
235.2M
↑ 69.72%
Total Liabilities
96.9M
↓ 1.74%
FY20Y/Y Change
Total Assets
150.2M
↓ 36.17%
Total Liabilities
105.7M
↑ 9.09%
FY21Y/Y Change
Total Assets
211.5M
↑ 40.85%
Total Liabilities
120.3M
↑ 13.81%
FY22Y/Y Change
Total Assets
238.2M
↑ 12.61%
Total Liabilities
177.7M
↑ 47.71%
FY23Y/Y Change
Total Assets
159.8M
↓ 32.91%
Total Liabilities
140.9M
↓ 20.71%
Q2 FY23Q/Q Change
Total Assets
181.7M
↓ 11.15%
Total Liabilities
147.7M
↓ 10.14%
Q3 FY23Q/Q Change
Total Assets
164.3M
↓ 9.55%
Total Liabilities
135.3M
↓ 8.38%
Q4 FY23Q/Q Change
Total Assets
159.8M
↓ 2.78%
Total Liabilities
140.9M
↑ 4.17%
Q1 FY24Q/Q Change
Total Assets
184.7M
↑ 15.62%
Total Liabilities
147.5M
↑ 4.69%
Q2 FY24Q/Q Change
Total Assets
165.8M
↓ 10.25%
Total Liabilities
91.1M
↓ 38.26%
Q3 FY24Q/Q Change
Total Assets
153.3M
↓ 7.56%
Total Liabilities
88.4M
↓ 2.96%
FY18Y/Y Change
Operating Cash Flow
-51.7M
↑ 114.01%
Investing Cash Flow
-15.7M
↑ 184.01%
Financing Cash Flow
107.8M
↓ 11602.35%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 37.3%
Investing Cash Flow
-24.7M
↑ 57.48%
Financing Cash Flow
173.4M
↑ 60.86%
FY20Y/Y Change
Operating Cash Flow
-87.4M
↑ 23.05%
Investing Cash Flow
-5.0M
↓ 79.6%
Financing Cash Flow
1.3M
↓ 99.23%
FY21Y/Y Change
Operating Cash Flow
-10.9M
↓ 87.58%
Investing Cash Flow
-5.8M
↑ 15.34%
Financing Cash Flow
70.5M
↑ 5206.32%
FY22Y/Y Change
Operating Cash Flow
-45.8M
↑ 321.57%
Investing Cash Flow
-3.3M
↓ 42.81%
Financing Cash Flow
95.0M
↑ 34.69%
Q2 FY23Q/Q Change
Operating Cash Flow
-21.1M
↓ 32.83%
Investing Cash Flow
-1.1M
↑ 46.46%
Financing Cash Flow
1.9M
↑ 149.93%

Technicals Summary

Sell

Neutral

Buy

Precision Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Precision Biosciences Inc
Precision Biosciences Inc
-18.82%
-44.24%
-46.73%
-97.4%
-98.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.12%
-24.58%
-7.12%
15.69%
116.3%
Biontech Se
Biontech Se
-4.64%
15.06%
7.66%
-66.93%
422.85%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-19.77%
55.93%
41.76%
25.27%
116.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.29%
0.48%
25.55%
146.84%
108.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Precision Biosciences Inc
Precision Biosciences Inc
18.15
18.15
NA
1.03
0.24
-0.06
NA
8.67
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.02
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Precision Biosciences Inc
Precision Biosciences Inc
Buy
$55.7M
-98.09%
18.15
11.48%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
116.3%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
422.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
116.5%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
108.31%
32.84
-4.51%

Insights on Precision Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 49.89M → 576.0K (in $), with an average decrease of 98.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 32.74M → -16.42M (in $), with an average decrease of 150.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 41.8% return, outperforming this stock by 88.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 29.4% return, outperforming this stock by 126.8%

Institutional Holdings

  • HHG PLC

    8.25%

  • TANG CAPITAL MANAGEMENT LLC

    8.13%

  • Perceptive Advisors LLC

    5.56%

  • Aquilo Capital Management, LLC

    4.98%

  • Vanguard Group Inc

    3.44%

  • Alyeska Investment Group, L.P.

    2.30%

Company Information

precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.

Organization
Precision Biosciences Inc
Employees
108
CEO
Mr. Michael Amoroso
Industry
Biotechnology

FAQs